Navigation Links
Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease
Date:3/4/2009

Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources

WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share was driven by growth in the use of Teva's Azilect which is attributed to physicians' growing comfort with the drug and data attesting to its possible neuroprotective (disease-modifying) effects.

"Neurologists are likely the driving force behind this increase in Azilect prescription, as only eight percent of surveyed primary care physicians (PCPs) report using the drug," stated Madhuri Borde, Ph.D., analyst at Decision Resources. "In fact, Azilect prescriptions will likely continue to rise in the specialist setting as 55 percent of surveyed neurologists believe that the A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease (ADAGIO) trial results demonstrated Azilect has a disease-modifying effect and will increase their Azilect prescriptions as a result."

The new report entitled Treatment Algorithms in Parkinson's Disease also finds that surveyed neurologists and PCPs vary in their prescribing patterns of levodopa/carbidopa and non-ergotic dopamine agonists, which include Boehringer Ingelheim's Mirapex and GlaxoSmithKline's Requip/Requip XL, generics. Survey results show that PCPs rely heavily on levodopa/carbidopa formulations for early treatment of Parkinson's disease whereas neurologists more often turn to non-ergotic dopamine agonists. This difference in treatment patterns indicates a growth opportunity for non-ergotic dopamine agonists among PCPs.

"Our survey results indicate that PCPs need to be educated on the advantages of prescribing a non-ergotic dopamine agonist in the place of levodopa/carbidopa first line," added Dr. Borde. "Surveyed neurologists, on the other hand, have become very comfortable prescribing a non-ergotic dopamine agonist ahead of levodopa/carbidopa and some no longer even use the drug first line."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
2. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
3. Demand for VScan Dengue Fever Test Kits Increases
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
8. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
9. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
10. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
11. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27, 2017  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), ... of select chronic diseases utilizing its ProNeura™ long-term, ... U.S. Food & Drug Administration (FDA) has completed ... New Drug Application (IND) and has requested that ... pending submission of the requested information and the ...
(Date:2/28/2017)... Md. and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that Martine ... Therapeutics, will provide an overview and update on the company,s ... Health Care Conference in Boston, Massachusetts . ... 6, 2017, at 2:00 PM Eastern Time, and can be ...
(Date:2/28/2017)... Feb. 27, 2017 This report provides all ... its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... for entries to the 7th Edition of International Social Design Awards. , ... Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects and ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency ... Belmont, and Palo Alto, is proud to announce an important upgrade to its geographic ... for home care close to home, and by having city-specific pages, NuevaCare is answering ...
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
Breaking Medicine News(10 mins):